Plasmodium falciparum resistance to chloroquine and sulphadoxine–pyrimethamine has led
to the recent adoption of artemisinin-based combination therapies (ACTs) as the first line of …

Artemisinin combination therapies are the first-line treatments for uncomplicated
Plasmodium falciparum malaria in most malaria-endemic countries. Recently, partial …

Zika virus (ZIKV) infects fetal and adult human brain and is associated with serious
neurological complications. To date, no therapeutic treatment is available to treat ZIKV …

Infective diseases have become health threat of a global proportion due to appearance and
spread of microorganisms resistant to majority of therapeutics currently used for their …

The artemisinin-based combination therapies artemether-lumefantrine (AL) and
amodiaquine (AQ) plus artesunate have been adopted for treatment of Plasmodium …

A number of therapeutic drugs with different structures and mechanisms of action have been
reported to undergo metabolic activation by Phase I or Phase II drug-metabolizing enzymes …

Background Intermittent preventive treatment of malaria in children less than five years of
age (IPTc) has been investigated as a measure to control the burden of malaria in the Sahel …

The choice of partner drug is critical for artemisinine-based combination therapy (ACT) to
remain effective and amodiaquine (AQ) is one important candidate to evaluate. We treated …

As drug-resistant falciparum malaria has continued to evolve and spread worldwide,
artemisinin-based combination therapies (ACT) have become the centerpiece of global …

Discovery and development of antimalarial drugs have long been dominated by single-
target therapy. Continuous effort has been made to explore and identify different targets in …